Theriva Biologics Inc. (TOVX)
AMEX: TOVX
· Real-Time Price · USD
0.51
-0.02 (-3.76%)
At close: May 12, 2025, 3:59 PM
0.52
1.58%
Pre-market: May 13, 2025, 04:15 AM EDT
-3.76% (1D)
| Bid | 0.52 |
| Market Cap | 1.42M |
| Revenue (ttm) | 154K |
| Net Income (ttm) | -25.65M |
| EPS (ttm) | -19.03 |
| PE Ratio (ttm) | -0.03 |
| Forward PE | -0.09 |
| Analyst | Buy |
| Ask | 0.58 |
| Volume | 635,529 |
| Avg. Volume (20D) | 784,068 |
| Open | 0.54 |
| Previous Close | 0.53 |
| Day's Range | 0.50 - 0.56 |
| 52-Week Range | 0.50 - 12.25 |
| Beta | 1.15 |
About TOVX
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol TOVX
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for TOVX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts5 days ago
-20.59%
Theriva Biologics shares are trading lower after M...
Unlock content with
Pro Subscription
6 days ago
-40.44%
TOVX stock has given up its prior gain. Theriva Biologics shares were trading higher after the company announced VCN-01 was well tolerated with transient and reversible adverse events, meeting the primary safety endpoint.
1 year ago · proactiveinvestors.com
Theriva Biologics jumps on US FDA approval for pancreatic cancer treatmentTheriva Biologics Inc saw its shares surge over 70% higher in after-hours US trading following news that its lead clinical candidate, VCN-01, has been granted orphan drug designation by the US Food an...
